A Phase 3, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
Latest Information Update: 22 May 2024
At a glance
- Drugs Florzolotau (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Diagnostic use; Registrational
- Sponsors APRINOIA Therapeutics
- 20 May 2024 According to an APRINOIA Therapeutics media release, In Dec 2023, enrollment of Phase 3 trial to evaluate the efficacy and safety of APN-1607 for the diagnosis of Alzheimer's disease was completed in China and on Dec 8, 2023.
- 20 May 2024 Status changed to active, no longer recruiting, according to an APRINOIA Therapeutics media release
- 13 Sep 2022 Status changed from planning to recruiting.